Bulletin
Investor Alert

Market Pulse Archives

Aug. 10, 2022, 7:47 a.m. EDT

U.S. buys $26 million of Siga's intravenous treatment for monkeypox

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    SIGA Technologies Inc. (SIGA)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Siga Technologies Inc. /zigman2/quotes/201166334/composite SIGA -1.75% said Tuesday that the U.S. government is exercising the option to acquire $26 million of the company's intravenous monkeypox treatment and fund a post-marketing study for the therapy. Siga said it plans to deliver these Tpoxx doses in 2023. Siga's stock has soared 203.0% so far this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX +2.59% is down 13.5%.

/zigman2/quotes/201166334/composite
US : U.S.: Nasdaq
$ 10.12
-0.18 -1.75%
Volume: 1.37M
Oct. 3, 2022 4:00p
P/E Ratio
10.68
Dividend Yield
0.00%
Market Cap
$752.15 million
Rev. per Employee
$3.78M
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,678.43
+92.81 +2.59%
Volume: 2.22B
Oct. 3, 2022 7:15p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.